1. |
Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials[J]. Lancet, 2003, 362(9395): 1527- 1535.
|
2. |
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J]. Circulation, 2008, 117 (25): e510-e526.
|
3. |
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group[J]. Jama, 2000, 283(25): 1967-1975.
|
4. |
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial[J]. JAMA, 2003, 290(21): 2805-2816.
|
5. |
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients[J]. N Engl J Med, 2008, 359(23): 2417-2428.
|
6. |
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol[J]. Lancet, 2002, 359(9311): 995-1003.
|
7. |
Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes[J]. J Hum Hypertens, 2014, 28(8): 463-468.
|
8. |
Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and endstage renal disease: results from the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [J]. Hypertension, 2014, 64(5): 1012-1021.
|
9. |
Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis[J]. J Hum Hypertens, 2013, 31(4): 766-774.
|
10. |
Esler M, Jennings G, Lambert G, et al. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions[J]. Physiol Rev, 1990, 70(4): 963-985.
|
11. |
Grassi G, Vailati S, Bertinieri G, et al. Heart rate as marker of sympathetic activity[J]. J Hypertens, 1998, 16(11): 1635-1639.
|
12. |
Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension[J]. Circ Res, 2015, 116(6): 976-990.
|
13. |
Thomas P, Dasgupta I. The role of the kidney and the sympathetic nervous system in hypertension[J]. Pediatr Nephrol, 2015, 30(4): 549-560.
|
14. |
Sakakura K, Ladich E, Cheng Q, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man[J]. J Am Coll Cardiol, 2014, 64(7): 635-643.
|
15. |
DiBona GF, Kopp UC. Neural control of renal function[J]. Physiol Rev, 1997, 77(1): 75-197.
|
16. |
DiBona GF. Sympathetic nervous system and the kidney in hypertension[J]. Curr Opin Nephrol Hypertens, 2002, 11(2): 197-200.
|
17. |
Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J]. Lancet, 2009, 373(9671): 1275-1281.
|
18. |
Symplicity HTN-2 investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial[J]. Lancet, 2010, 376(9756): 1903-1909.
|
19. |
Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension[J]. N Eng J Med, 2014, 370(15): 1393-1401.
|
20. |
Olsen LK, Kamper AL, Svendsen JH, et al. Renal denervation[J]. Eur J Int Med, 2015, 26(2): 95-105.
|
21. |
Symplicity HTN-1 investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months[J]. Hypertension, 2011, 57(5): 911-917.
|
22. |
Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study[J]. Lancet, 2014, 383(9917): 622-629.
|
23. |
Esler MD, Bohm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial[J]. Eur Heart J, 2014, 35(26): 1752-1759.
|
24. |
Bohm M, Mahfoud F, Ukena C, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension[J]. Hypertension, 2015, 65(4): 766-774.
|
25. |
Mancia G, Mahfoud F, Narkiewicz K, et al. Long-term effects of renal artery denervation in real world patients with uncontrolled hypertension from the global symplicity registry[J]. J Hypertens, 2015, 33(Suppl 1): e49.
|
26. |
Iliescu R, Lohmeier TE, Tudorancea I, et al. Renal denervation for the treatment of resistant hypertension: review and clinical perspective[J]. Am J Physiol Renal Physiol, 2015, 309(7): F583-F594.
|
27. |
Lobo MD, de Belder MA, Cleveland T, et al. Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension[J]. Heart, 2015, 101(1): 10-16.
|
28. |
Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial[J]. Eur Heart J, 2015, 36(4): 219-227.
|
29. |
Pekarskiy S, Baev A, Mordovin V, et al. Failure of renal denervation in Symplicity HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology[J]. J Hypertens, 2015, 33(Suppl 1): e108.
|
30. |
Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the Symplicity HTN-3 trial[J]. Eur Heart J, 2015, 36(4): 219-227.
|
31. |
Tsioufis CP, Papademetriou V, Dimitriadis KS, et al. Catheter-based renal denervation for resistant hypertension: twenty-four month results of the EnligHTN Ⅰ first-in-human study using a multielectrode ablation system[J]. Int J Cardiol, 2015, 201(1): 345-350.
|
32. |
Lobo M, Saxena M, Jain AJ, et al. Safety and performance of the enlightn renal denervation system in patients with severe uncontrolled hypertension: 12 month results from the Enlightn Ⅱ study[J]. J Hypertens, 2015, 33(Suppl 1): e51.
|
33. |
Fadl Elmula FE, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension[J]. Blood Press, 2015, 24(5): 263-274.
|